Microbial recognition and danger signals in sepsis and trauma.

[1]  L. Moldawer,et al.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome , 2017, Critical care medicine.

[2]  S. Opal,et al.  Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials* , 2016, Critical care medicine.

[3]  P. Pickkers,et al.  Plasma Nuclear and Mitochondrial DNA Levels, and Markers of Inflammation, Shock, and Organ Damage in Patients with Septic Shock , 2016, Shock.

[4]  Zhiguang Sun,et al.  The effect of early goal-directed therapy on mortality in patients with severe sepsis and septic shock: a meta-analysis. , 2016, The Journal of surgical research.

[5]  Yiran Huang,et al.  Serum levels of HSP70 and other DAMP proteins can aid in patient diagnosis after traumatic injury , 2016, Cell Stress and Chaperones.

[6]  H. Baker,et al.  Patterns of gene expression among murine models of hemorrhagic shock/trauma and sepsis. , 2016, Physiological genomics.

[7]  L. Moldawer,et al.  The future of murine sepsis and trauma research models , 2015, Journal of leukocyte biology.

[8]  V. Nizet,et al.  Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec‐5 and Siglec‐14 , 2015, The EMBO journal.

[9]  J. Pittet,et al.  The coagulopathy of acute sepsis , 2015, Current opinion in anaesthesiology.

[10]  D. Kaufman,et al.  Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants , 2015, Expert opinion on biological therapy.

[11]  Y. Vodovotz,et al.  Injury‐induced MRP8/MRP14 stimulates IP‐10/CXCL10 in monocytes/macrophages , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  M. Boerries,et al.  S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4 , 2014, EMBO molecular medicine.

[13]  J. Marshall.  Why have clinical trials in sepsis failed? , 2014, Trends in molecular medicine.

[14]  N. Miyagawa,et al.  Plasma mitochondrial DNA levels in patients with trauma and severe sepsis: time course and the association with clinical status. , 2013, Journal of critical care.

[15]  A. Fabio,et al.  S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. , 2013, Journal of neurotrauma.

[16]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[17]  C. Hauser,et al.  Plasma Bacterial and Mitochondrial DNA Distinguish Bacterial Sepsis From Sterile Systemic Inflammatory Response Syndrome and Quantify Inflammatory Tissue Injury in Nonhuman Primates , 2013, Shock.

[18]  D. Kontoyiannis,et al.  Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ. , 2012, Diagnostic microbiology and infectious disease.

[19]  T. van der Poll,et al.  Myeloid-Related Protein-14 Contributes to Protective Immunity in Gram-Negative Pneumonia Derived Sepsis , 2012, PLoS pathogens.

[20]  Matthew Taecker.  Hospitalizations, Costs, and Outcomes of Severe Sepsis in the United States 2003 to 2007 , 2012 .

[21]  K. Tracey,et al.  Novel role of PKR in inflammasome activation and HMGB1 release , 2012, Nature.

[22]  D. Pisetsky.  The origin and properties of extracellular DNA: from PAMP to DAMP. , 2012, Clinical immunology.

[23]  Cheng-Hsien Lu,et al.  Plasma nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients in the emergency room , 2012, Journal of Translational Medicine.

[24]  L. Moldawer,et al.  Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care , 2012, The journal of trauma and acute care surgery.

[25]  L. Bekker,et al.  Adjunctive interferon-&ggr; immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial , 2012, AIDS.

[26]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.

[27]  T. Lagu,et al.  Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007 , 2012, Critical care medicine.

[28]  D. Chaussabel,et al.  Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. , 2011, The Journal of clinical investigation.

[29]  V. V. van Hinsbergh.  Endothelium—role in regulation of coagulation and inflammation , 2011, Seminars in immunopathology.

[30]  B. Bogerts,et al.  Human CD8+ T cells and NK cells express and secrete S100B upon stimulation , 2011, Brain, Behavior, and Immunity.

[31]  R. Donato,et al.  S100B protein regulates myoblast proliferation and differentiation by activating FGFR1 in a bFGF-dependent manner , 2011, Journal of Cell Science.

[32]  J. Casanova,et al.  Infectious Diseases in Patients with IRAK-4, MyD88, NEMO, or IκBα Deficiency , 2011, Clinical Microbiology Reviews.

[33]  D. Souza,et al.  Neuron-Specific Enolase, S100B, and Glial Fibrillary Acidic Protein Levels as Outcome Predictors in Patients With Severe Traumatic Brain Injury , 2011, Neurosurgery.

[34]  S. Akira,et al.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.

[35]  C. Coopersmith,et al.  The Role of Heat Shock Protein 70 in Mediating Age-Dependent Mortality in Sepsis , 2011, The Journal of Immunology.

[36]  S. Reed,et al.  Use of defined TLR ligands as adjuvants within human vaccines , 2011, Immunological reviews.

[37]  C. Lombard,et al.  The interferon‐alpha and interleukin‐10 responses in neonates differ from adults, and their production remains partial throughout the first 18 months of life , 2010, Clinical and experimental immunology.

[38]  T. Beems,et al.  GFAP and S100B are biomarkers of traumatic brain injury , 2010, Neurology.

[39]  J. L. Ding,et al.  SARM inhibits both TRIF‐ and MyD88‐mediated AP‐1 activation , 2010, European journal of immunology.

[40]  K. Fitzgerald.  NLR‐containing inflammasomes: Central mediators of host defense and inflammation , 2010, European journal of immunology.

[41]  W. Junger,et al.  Circulating Mitochondrial DAMPs Cause Inflammatory Responses to Injury , 2009, Nature.

[42]  M. Boermeester,et al.  Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. , 2009, American journal of respiratory and critical care medicine.

[43]  M. Cohen,et al.  Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion , 2009, Critical care.

[44]  A. Weyrich,et al.  Comment on Chapter 5 , 1999 .

[45]  M. Sayre,et al.  Level I versus Level II trauma centers: an outcomes-based assessment. , 2009, The Journal of trauma.

[46]  Xian Chen,et al.  Modulation of TLR Signaling by Multiple MyD88-Interacting Partners Including Leucine-Rich Repeat Fli-I-Interacting Proteins1 , 2009, The Journal of Immunology.

[47]  S. Yamasaki,et al.  Mincle is an ITAM-coupled activating receptor that senses damaged cells , 2008, Nature Immunology.

[48]  M. Cesari,et al.  Interferon-γ and Granulocyte-Macrophage Colony Stimulating Factor Therapy in Three Patients with Pulmonary Aspergillosis , 2008, Infection.

[49]  E. Ruokonen,et al.  Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. , 2008, Clinical chemistry.

[50]  T. Billiar,et al.  HMGB1: Endogenous Danger Signaling , 2008, Molecular medicine.

[51]  J. Tschopp,et al.  The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response , 2008, Nature.

[52]  S. Akira,et al.  TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β , 2008, Nature Immunology.

[53]  J. Tschopp,et al.  The inflammasome: a danger sensing complex triggering innate immunity. , 2007, Current opinion in immunology.

[54]  Michael G. Katze,et al.  Distinct RIG-I and MDA5 Signaling by RNA Viruses in Innate Immunity , 2007, Journal of Virology.

[55]  J. Catravas,et al.  Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. , 2007, American journal of respiratory and critical care medicine.

[56]  W. Nacken,et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.

[57]  E. Ellis,et al.  S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti‐S100 increases trauma‐induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons , 2007, Journal of neurochemistry.

[58]  F. Massin,et al.  High-mobility group box 1 protein plasma concentrations during septic shock , 2007, Intensive Care Medicine.

[59]  J. Carcillo,et al.  Extracellular heat shock protein 60 (Hsp60) levels in children with septic shock , 2007, Inflammation Research.

[60]  N. Volkmann,et al.  Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. , 2007, Molecular cell.

[61]  A. Prusa,et al.  Immaturity of infection control in preterm and term newborns is associated with impaired toll-like receptor signaling. , 2007, Journal of Infectious Diseases.

[62]  S. Akira,et al.  Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2 , 2007, Proceedings of the National Academy of Sciences.

[63]  J. Kirby,et al.  Toll‐like receptor interactions: tolerance of MyD88‐dependent cytokines but enhancement of MyD88‐independent interferon‐β production , 2007 .

[64]  David Miller,et al.  Critical Role for Cryopyrin/Nalp3 in Activation of Caspase-1 in Response to Viral Infection and Double-stranded RNA*> , 2006, Journal of Biological Chemistry.

[65]  D. Missiakas,et al.  Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins , 2006, Proceedings of the National Academy of Sciences.

[66]  K. Tracey,et al.  HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2 , 2006, Shock.

[67]  P. Wischmeyer,et al.  Effects of HSP70.1/3 gene knockout on acute respiratory distress syndrome and the inflammatory response following sepsis. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[68]  K. Tracey,et al.  Anti-HMGB1 Neutralizing Antibody Ameliorates Gut Barrier Dysfunction and Improves Survival after Hemorrhagic Shock , 2006, Molecular medicine.

[69]  E. Abraham,et al.  High mobility group box 1 protein interacts with multiple Toll-like receptors. , 2006, American journal of physiology. Cell physiology.

[70]  Stefan Bauer,et al.  CpG motif‐independent activation of TLR9 upon endosomal translocation of “natural” phosphodiester DNA , 2006, European journal of immunology.

[71]  Peter Rhee,et al.  Relationship between American College of Surgeons trauma center designation and mortality in patients with severe trauma (injury severity score > 15). , 2006, Journal of the American College of Surgeons.

[72]  Daniel O Scharfstein,et al.  A national evaluation of the effect of trauma-center care on mortality. , 2006, The New England journal of medicine.

[73]  S. Akira,et al.  The RNA Helicase Lgp2 Inhibits TLR-Independent Sensing of Viral Replication by Retinoic Acid-Inducible Gene-I1 , 2005, The Journal of Immunology.

[74]  I. Grivicich,et al.  Serum Hsp70 as an early predictor of fatal outcome after severe traumatic brain injury in males. , 2005, Journal of neurotrauma.

[75]  J. Carcillo,et al.  Extracellular hsp70 levels in children with septic shock* , 2005, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[76]  K. Tracey,et al.  Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock* , 2005, Critical care medicine.

[77]  S. Andrew,et al.  Hsp70 release from peripheral blood mononuclear cells. , 2004, Biochemical and biophysical research communications.

[78]  A. Raabe,et al.  GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. , 2004, Journal of neurotrauma.

[79]  J. Kuja-Panula,et al.  Regulation of monocyte migration by amphoterin (HMGB1). , 2004, Blood.

[80]  T. Beems,et al.  Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury , 2004, Neurology.

[81]  Akiko Iwasaki,et al.  Recognition of single-stranded RNA viruses by Toll-like receptor 7. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[82]  A. Zychlinsky,et al.  Neutrophil Extracellular Traps Kill Bacteria , 2004, Science.

[83]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[84]  S. Akira,et al.  Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. , 2004, Blood.

[85]  S. Akira,et al.  Toll-like Receptor 9–mediated Recognition of Herpes Simplex Virus-2 by Plasmacytoid Dendritic Cells , 2003, The Journal of experimental medicine.

[86]  邊見 弘明,et al.  A Toll-like receptor recognizes bacterial DNA , 2003 .

[87]  W. Mauritz,et al.  Serum S 100 B: A Marker of Brain Damage in Traumatic Brain Injury with and without Multiple Trauma , 2003, Shock.

[88]  H. Redmond,et al.  Cutting Edge: Bacterial Lipoprotein Induces Endotoxin-Independent Tolerance to Septic Shock , 2003, The Journal of Immunology.

[89]  R. Flavell,et al.  The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors , 2002, Nature.

[90]  K. Frei,et al.  Toll-like receptor 2-deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation. , 2002, The Journal of infectious diseases.

[91]  S. Akira,et al.  Essential role of MD-2 in LPS responsiveness and TLR4 distribution , 2002, Nature Immunology.

[92]  G. Zimmerman,et al.  The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis , 2002, Critical care medicine.

[93]  Michael Rehli,et al.  Novel Signal Transduction Pathway Utilized by Extracellular HSP70 , 2002, The Journal of Biological Chemistry.

[94]  D. Morabito,et al.  Serum levels of Hsp 72 measured early after trauma correlate with survival. , 2002, The Journal of trauma.

[95]  Isaac Ginsburg,et al.  Role of lipoteichoic acid in infection and inflammation. , 2002, The Lancet. Infectious diseases.

[96]  E. Lander,et al.  Human macrophage activation programs induced by bacterial pathogens , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[97]  B. Echtenacher,et al.  Differences in Innate Defense Mechanisms in Endotoxemia and Polymicrobial Septic Peritonitis , 2001, Infection and Immunity.

[98]  T. Shimazu,et al.  Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis. , 2001, The Journal of trauma.

[99]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[100]  A. Schmidt,et al.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.

[101]  S. Müller,et al.  The High Mobility Group (Hmg) Boxes of the Nuclear Protein Hmg1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells , 2001, The Journal of cell biology.

[102]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[103]  A. Ebert,et al.  Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury , 2001, Journal of neurology, neurosurgery, and psychiatry.

[104]  S. Akira,et al.  Cutting Edge: TLR2-Deficient and MyD88-Deficient Mice Are Highly Susceptible to Staphylococcus aureus Infection1 , 2000, The Journal of Immunology.

[105]  K. Tracey,et al.  Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation1 , 2000, The Journal of Immunology.

[106]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[107]  Stuart K. Calderwood,et al.  HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine , 2000, Nature Medicine.

[108]  Y. Lo,et al.  Plasma DNA as a prognostic marker in trauma patients. , 2000, Clinical chemistry.

[109]  Charles A. Janeway,et al.  Innate immunity: Lipoproteins take their Toll on the host , 1999, Current Biology.

[110]  S. Akira,et al.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.

[111]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[112]  S. Akira,et al.  Unresponsiveness of MyD88-deficient mice to endotoxin. , 1999, Immunity.

[113]  J. Crowley,et al.  The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. , 1999, The Journal of clinical investigation.

[114]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[115]  M. Rothe,et al.  Peptidoglycan- and Lipoteichoic Acid-induced Cell Activation Is Mediated by Toll-like Receptor 2* , 1999, The Journal of Biological Chemistry.

[116]  S. Akira,et al.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.

[117]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[118]  K. Asadullah,et al.  Monocyte deactivation in septic patients: Restoration by IFN-γ treatment , 1997, Nature Medicine.

[119]  J. Silver,et al.  Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. , 1996, Immunity.

[120]  Craig R. Smith,et al.  Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial , 1995 .

[121]  N. MacIntyre,et al.  A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.

[122]  F. Lewis,et al.  Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. , 1994, Archives of surgery.

[123]  J. L. Rodriguez,et al.  A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients☆ , 1992 .

[124]  M. A. Martin,et al.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. , 1991, JAMA.

[125]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[126]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[127]  T. van der Poll,et al.  Activation of coagulation after administration of tumor necrosis factor to normal subjects. , 1990, The New England journal of medicine.

[128]  William F. Snow,et al.  The evolution of modern medicine , 1977 .

[129]  제임스 스코트 크라우,et al.  Production of Antibodies , 1942, Nature.

[130]  S. Lemeshow,et al.  Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. , 2015, Critical care medicine.

[131]  M. Boerries,et al.  S 100 A 1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4 , 2014 .

[132]  E. Abraham,et al.  Differential activation of RAGE by HMGB1 modulates neutrophil-associated NADPH oxidase activity and bacterial killing. , 2012, American journal of physiology. Cell physiology.

[133]  V. Hornung,et al.  RNA recognition via TLR7 and TLR8. , 2008, Handbook of experimental pharmacology.

[134]  J. Stockman.  Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial , 2008 .

[135]  H. D. Liggitt,et al.  Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[136]  J. Kirby,et al.  Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production. , 2007, Immunology.

[137]  Jay Steingrub,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005 .

[138]  R. Chiu,et al.  Plasma mitochondrial DNA concentrations after trauma. , 2004, Clinical chemistry.

[139]  K. Miyake.  Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. , 2003, International immunopharmacology.

[140]  V. Fadok,et al.  Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. , 2002, The Journal of clinical investigation.

[141]  T. Shimazu,et al.  Enhanced expression of heat shock proteins in leukocytes from trauma patients. , 2001, The Journal of trauma.

[142]  L. Mascia,et al.  Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. , 1998, Acta neurochirurgica. Supplement.

[143]  K. Asadullah,et al.  Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. , 1997, Nature medicine.

[144]  M. Doerfler,et al.  The bactericidal/permeability increasing protein of neutrophils is a potent antibacterial and anti-endotoxin agent in vitro and in vivo. , 1994, Progress in clinical and biological research.

[145]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[146]  C. Janeway.  Approaching the asymptote? Evolution and revolution in immunology. , 1989, Cold Spring Harbor symposia on quantitative biology.

[147]  W. Osler.  The evolution of modern medicine : a series of lectures delivered at Yale University on the Silliman Foundation in April, 1913 , 1921 .